New Targeted Therapies for Uncontrolled Asthma.
Activated-Leukocyte Cell Adhesion Molecule
/ immunology
Anti-Asthmatic Agents
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antigens, CD
/ immunology
Antigens, Differentiation, T-Lymphocyte
/ immunology
Asthma
/ drug therapy
Cytokines
/ antagonists & inhibitors
DNA, Catalytic
/ therapeutic use
Eosinophils
/ immunology
GATA3 Transcription Factor
Humans
Imatinib Mesylate
/ therapeutic use
Indoleacetic Acids
/ therapeutic use
Interleukin-17
/ antagonists & inhibitors
Interleukin-6
/ immunology
Lymphocytes
/ immunology
Mast Cells
/ immunology
Molecular Targeted Therapy
Omalizumab
/ therapeutic use
Proto-Oncogene Proteins c-kit
/ antagonists & inhibitors
Pyridines
/ therapeutic use
Receptors, Immunologic
/ antagonists & inhibitors
Receptors, Interleukin-17
/ antagonists & inhibitors
Receptors, Prostaglandin
/ antagonists & inhibitors
Ribonucleases
/ therapeutic use
Th2 Cells
/ immunology
Tumor Necrosis Factor Ligand Superfamily Member 15
/ antagonists & inhibitors
Asthma
Cytokine
Eosinophil
IL-33
Prostaglandin D2
TSLP
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
Historique:
received:
19
11
2018
revised:
11
03
2019
accepted:
11
03
2019
entrez:
12
5
2019
pubmed:
12
5
2019
medline:
18
8
2020
Statut:
ppublish
Résumé
Mechanistic studies have improved our understanding of molecular and cellular components involved in asthma and our ability to treat severe patients. An mAb directed against IgE (omalizumab) has become an established add-on therapy for patients with uncontrolled allergic asthma and mAbs specific for IL-5 (reslizumab, mepolizumab), IL-5R (benralizumab), and IL-4R (dupilumab) have been approved as add-on treatments for uncontrolled eosinophilic (type 2) asthma. While these medications have proven highly effective, some patients with severe allergic and/or eosinophilic asthma, as well as most patients with severe non-type-2 disease, have poorly controlled disease. Agents that have recently been evaluated in clinical trials include an antibody directed against thymic stromal lymphopoietin, small molecule antagonists to the chemoattractant receptor-homologous molecule expressed on T
Identifiants
pubmed: 31076057
pii: S2213-2198(19)30286-7
doi: 10.1016/j.jaip.2019.03.022
pii:
doi:
Substances chimiques
Activated-Leukocyte Cell Adhesion Molecule
0
Anti-Asthmatic Agents
0
Antibodies, Monoclonal, Humanized
0
Antigens, CD
0
Antigens, Differentiation, T-Lymphocyte
0
CD6 antigen
0
Cytokines
0
DNA, Catalytic
0
GATA3 Transcription Factor
0
IL17RA protein, human
0
Indoleacetic Acids
0
Interleukin-17
0
Interleukin-6
0
Pyridines
0
Receptors, Immunologic
0
Receptors, Interleukin-17
0
Receptors, Prostaglandin
0
TSLP protein, human
0
Tumor Necrosis Factor Ligand Superfamily Member 15
0
Omalizumab
2P471X1Z11
fevipiprant
2PEX5N7DQ4
reslizumab
35A26E427H
dupilumab
420K487FSG
brodalumab
6ZA31Y954Z
benralizumab
71492GE1FX
Imatinib Mesylate
8A1O1M485B
mepolizumab
90Z2UF0E52
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Ribonucleases
EC 3.1.-
SB010 DNAzyme
EC 3.1.-
tezepelumab
RJ1IW3B4QX
itolizumab
XQQ2RHV14N
prostaglandin D2 receptor
XZF106QU24
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1394-1403Informations de copyright
Copyright © 2019. Published by Elsevier Inc.